Nagoya Medical Center, Nagoya, Japan.
J Thromb Haemost. 2011 Jul;9 Suppl 1:352-63. doi: 10.1111/j.1538-7836.2011.04362.x.
Over the past 100 years, remarkable advances have been made in our understanding of the mechanisms of blood coagulation. Starting with the early clinical observations of rare patients with hereditary clotting disorders, our knowledge has increased in keeping pace with the introduction of new technologies: from simple laboratory tests to protein chemistry, to DNA technology, and to gene targeting technology. Advances in basic research have been successfully translated into improved methods for the diagnosis of bleeding disorders as well as thrombosis, and the development of recombinant clotting factors for replacement therapy in patients with haemophilia. New promising anticoagulants have also been developed for the treatment of thrombotic disorders. Based on the unique nature of blood coagulation research the close interactions and collaborations between basic scientists and clinicians have played a major role in these developments. It is anticipated that blood coagulation research will continue to play a leading role in promoting better care of the patients with bleeding disorders or thromboembolism.
在过去的 100 年里，我们对凝血机制的理解取得了显著的进展。从早期对遗传性凝血障碍罕见患者的临床观察开始，我们的知识随着新技术的引入而不断增加：从简单的实验室测试到蛋白质化学，再到 DNA 技术和基因靶向技术。基础研究的进展成功地转化为改善出血性疾病和血栓形成的诊断方法，以及为血友病患者开发重组凝血因子进行替代治疗。新型有前途的抗凝剂也已开发用于治疗血栓性疾病。基于凝血研究的独特性质，基础科学家和临床医生之间的密切互动和合作在这些发展中发挥了重要作用。预计凝血研究将继续在改善出血性疾病或血栓栓塞患者的治疗方面发挥主导作用。
